InvestSMART

Compumedics Limited (ASX:CMP)

ALERT: Price-sensitive ASX Announcement for CMP
Current share price for CMP : $0.225 -0.06 (-21.05%)+
Announcement
Release
21 Apr 2026 9:38AM
Price at Release
$0.285
Full Release
download
Summary
Compumedics Limited's business update for April 2026 highlights strong demand across its platforms, although some timing-related issues have impacted revenue recognition for FY26. The company maintains robust sales momentum, particularly in its sleep and neurology platforms, and is continuing to expand its SaaS and connected platforms like Somfit and Nexus 360 to enhance recurring revenue streams. The high-value MEG (Magnetoencephalography) business faces scheduling delays due to supply chain constraints, particularly helium availability, pushing some revenue into FY27. Leadership changes and cost realignments have been implemented in the US to boost performance. Despite these challenges, Compumedics remains optimistic about achieving 22% to 28% revenue growth over FY25 and expects EBITDA between $5.5 million and $7 million. Liquidity is solid with $10 to $11 million available, supported by MEG cash receipts and expanded banking facilities. The company is focused on strategic execution and growth initiatives to improve its performance in FY27.
Key Points
  • Compumedics reports strong demand across platforms despite timing issues impacting FY26.
  • Sales momentum continues in sleep and neurology platforms, with growth in SaaS and annuity revenues.
  • MEG business experiences delays due to helium supply constraints, deferring some revenue to FY27.
  • Leadership changes and cost realignment in the US aim to improve performance.
  • Expected revenue growth for FY26 is 22% to 28% over FY25, with EBITDA between $5.5 million and $7 million.
  • Company maintains strong liquidity with $10 to $11 million available.
  • Focus remains on strategic execution and growth initiatives for improved performance in FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.